Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Gastroenterology

• Publication date

  1993-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0016-5085(93)90411-5PMID 8425685
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nonparametric Statistics for the Behavioral Sciences

  2022cited by this paper
• Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives.

  1992cited by this paper
• Mesalazine: a global safety evaluation.

  1990cited by this paper
• [Azathioprine, 6-mercaptopurine, and inflammatory diseases of the intestine].

  1990cited by this paper
• Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms.

  1988cited by this paper
• 5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa.

  1987cited by this paper
• A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease.

  1986cited by this paper
• Effect of a slow-release 5'-aminosalicylic acid preparation on disease activity in Crohn's disease.

  1986cited by this paper
• Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties.

  1986cited by this paper
• Renal function was not impaired by treatment with 5-aminosalicylic acid in rats and man

  1984cited by this paper
• European cooperative Crohn's disease study (ECCDS) : Results of drug treatment

  1984cited by this paper
• European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment.

  1984cited by this paper
• Risk factors for postoperative recurrence of Crohn's disease.

  1983cited by this paper
• Treatment of Crohn's disease with peroral 5-aminosalicylic acid.

  1983cited by this paper
• [Effect of levamisole on the prevention of developmental flare-ups in quiescent Crohn's disease: a prospective multicenter controlled trial in 155 patients].

  1983cited by this paper
• 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans.

  1982cited by this paper
• Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study.

  1981cited by this paper
• Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI).

  1979cited by this paper
• National Cooperative Crohn's Disease Study: results of drug treatment.

  1979cited by this paper
• A trial of sulfasalazine as adjunctive therapy in Crohn's disease.

  1979cited by this paper
• The Long-term Prophylactic Effect of Salazosulfapyridine (SalazopyrinR) in Primarily Resected Patients with Crohn's Disease

  1978cited by this paper
• Sulphasalazine in asymptomatic Crohn's disease. A multicentre trial.

  1977cited by this paper
• Postoperative treatment with corticosteroids and salazosulphapyridine (Salazopyrin) after radical resection for Crohn's disease.

  1976cited by this paper
• The clinical effect of salazosulphapyridine (Salazopyrin r) in Crohn's disease. A controlled double-blind study.

  1974cited by this paper
• Nephrotoxic Lesions from 5-Aminosalicylic Acid

  1972cited by this paper
• Regression Models and Life-Tables

  1972cited by this paper
• Recurrence of Crohn's disease after primary excisional surgery

  1971cited by this paper
• Antimalarial therapy and early retinal changes in patients with rheumatoid arthritis.

  1966cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• 5-Aminosalicylates for non-Surgical Patients With Active or Quiescent Crohn's Disease: An Overview Of Systematic Reviews (Umbrella Review).

  2025cites this paper
• Patent Landscaping of Time-dependent Mesalamine Prolonged-release Granules: A Case Study for Generic Formulation Development

  2025cites this paper
• ACG Clinical Guideline: Management of Crohn's Disease in Adults

  2025cites this paper
• The GETAID: 40 years of a family story in IBD.

  2024cites this paper
• A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation

  2022cites this paper
• Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease.

  2019cites this paper
• 5 - آمینوسالیسیلیک اسید برای حفظ بهبودی ناشی از جراحی در بیماری کرون

  2019cites this paper
• Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn’s Disease: A Systematic Review

  2018cites this paper
• ACG Clinical Guideline: Management of Crohn’s Disease in Adults

  2018cites this paper
• United States Patent ( 10 ) Patent No . : US 7928 , 092 B 2

  2017cites this paper
• Systematic review with meta‐analysis: placebo rates in induction and maintenance trials of Crohn's disease

  2017cites this paper
• Inflammatory bowel diseases: current therapeutic approaches and potential of using stem cells

  2017cites this paper
• Aminosalicylates for induction of remission or response in Crohn's disease.

  2016cites this paper
• Recent advances in clinical practice: a systematic review of isolated colonic Crohn's disease: the third IBD?

  2016cites this paper
• Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease.

  2016cites this paper
• Systematic review with network meta‐analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease

  2015cites this paper
• The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy.

  2015cites this paper
• Developing healthcare non-technical skills training through educational innovation and synthesis of educational research

  2014cites this paper
• Commentaries on "Workshop report: developing a pediatric inflammatory bowel diseases network and data platform in Canada": networking in pediatric inflammatory bowel disease: the French GETAID Pédiatrique experience.

  2012cites this paper
• Commentaries on "Workshop report: developing a pediatric inflammatory bowel diseases network and data platform in Canada": pediatric inflammatory bowel disease networks: raising the bar.

  2012cites this paper
• Randomized controlled trials in maintenance of remission in Crohn's disease.

  2012cites this paper
• Inflammatory bowel disease therapy: current state-of-the-art

  2011cites this paper
• Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease.

  2011cites this paper
• Efficacy of 5-Aminosalicylates in Crohn's Disease: Systematic Review and Meta-Analysis

  2011cites this paper
• An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease

  2011cites this paper
• Searching for the delta: 5-aminosalicylic Acid therapy for Crohn's disease.

  2011cites this paper
• Update on the Management of Crohn’s Disease

  2011cites this paper
• Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial

  2010cites this paper
• Current therapeutic approaches in inflammatory bowel disease.

  2010cites this paper
• Estimating the prevalence of inflammatory bowel disease in Portugal using a pharmaco‐epidemiological approach

  2010cites this paper
• The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management.

  2010cites this paper
• What is the optimal therapy for Crohn’s disease: step-up or top-down?

  2010cites this paper
• CONSENSUS GUIDELINES FOR THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASE Brazilian Study Group of Inflammatory Bowel Diseases *

  2010cites this paper
• Consensus guidelines for the management of inflammatory bowel disease.

  2010cites this paper
• INFLAMMATORY BOWEL DISEASES

  2009cites this paper
• Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial.

  2009cites this paper
• Place des 5-ASA dans le traitement des maladies inflammatoires cryptogénétiques de l’intestin

  2009cites this paper
• Maintenance of Medically Induced Remission of Crohn’s Disease

  2008cites this paper
• Effect of 5-aminosalicylates on renal function in patients with inflammatory bowel disease: 4-year follow-up study.

  2008cites this paper
• Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis

  2007cites this paper
• Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn’s disease

  2007cites this paper
• Nonadherence With Thiopurine Immunomodulator and Mesalamine Medications in Children with Crohn Disease

  2007cites this paper
• Medical management of mild to moderate Crohn’s disease: evidence‐based treatment algorithms for induction and maintenance of remission

  2007cites this paper
• 5‐Aminosalicylates and renal function in inflammatory bowel disease: A systematic review

  2007cites this paper
• “Mind the Gap”: An Unmet Need for New Therapy in IBD

  2007cites this paper
• Outcomes of placebo therapy in inflammatory bowel disease

  2006cites this paper
• European evidence based consensus on the diagnosis and management of Crohn’s disease: current management

  2006cites this paper
• Systematic review: the use of mesalazine in inflammatory bowel disease

  2006cites this paper
• Mesalamine delivery systems: do they really make much difference?

  2005cites this paper
• Doença de Crohn em lactentes: relato de caso

  2005cites this paper
• Debate: Should Mesalamine Be Used in Crohn's Disease?: Comments and Conclusions

  2005cites this paper
• Maintenance of Remission in Crohn’s Disease

  2005cites this paper
• Mesalamine derivatives in the treatment of Crohn's disease.

  2004cites this paper
• Review article: chronic active disease and maintaining remission in Crohn's disease.

  2004cites this paper
• Aminosalicylate Treatment in IBD continued ability to inhibit the activation of nuclear factor

  2004cites this paper
• Systematic review: how effective are the usual treatments for Crohn's disease?

  2004cites this paper
• Advances in the treatment of Crohn's disease.

  2004cites this paper
• Enfermedad de Crohn. Manifestaciones clínicas

  2004cites this paper
• Chronic active disease and maintaining remission in Crohn's disease

  2004cites this paper
• dvances in the Treatment of Crohn ’ s Disease

  2004cites this paper
• How effective are the usual treatments for Crohn's disease?

  2004cites this paper
• Evidence-based treatment algorithm for mild to moderate Crohn's disease.

  2003cites this paper
• Remissionserhaltung

  2003cites this paper
• Clinical pharmacology in inflammatory bowel disease: optimizing current medical therapy

  2003cites this paper
• Maintenance treatment of Crohn's disease

  2003cites this paper
• Gastrointestinal transit and release of 5‐aminosalicylic acid from 153Sm‐labelled mesalazine pellets vs. tablets in male healthy volunteers

  2003cites this paper
• Operations for Crohn's colitis: limited resection and preservation of anorectal function.

  2003cites this paper
• Therapy of Crohn’s disease in childhood

  2002cites this paper
• Inflammatory bowel disease. Medical therapy of specific clinical presentations.

  2002cites this paper
• Olsalazine was not better than placebo in maintaining remission in inactive Crohn disease.

  2002cites this paper
• Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review.

  2002cites this paper
• Olsalazine was not better than placebo in maintaining remission in inactive Crohn disease

  2002cites this paper
• Monitoring for drug side‐effects in inflammatory bowel disease

  2002cites this paper
• New steroids and new salicylates in inflammatory bowel disease: a critical appraisal

  2002cites this paper
• REVIEW: Role of 5-Aminosalicylic Acid (5-ASA) in Treatment of Inflammatory Bowel Disease: A Systemic Review

  2002cites this paper
• Review article: monitoring for drug side-effects in inflammatory bowel disease.

  2002cites this paper
• A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease.

  2002cites this paper
• Medical therapy for Crohn's disease: the state of the art.

  2001cites this paper
• Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study

  2001cites this paper
• Conventional treatment of Crohn's disease: objectives and outcomes.

  2001cites this paper
• 5-Aminosalicylates in inflammatory bowel disease: choosing the right dose.

  2001cites this paper
• Objectives and Outcomes in the Conventional Treatment of Pediatric Crohn's Disease

  2001cites this paper
• 5-Aminosalicylates in inflammatory bowel: disease: Choosing choosing the right dose

  2001cites this paper
• Does Adjuvant Nutritional Support Diminish Steroid Dependency in Crohn Disease

  2001cites this paper
• Does adjuvant nutritional support diminish steroid dependency in Crohn disease?

  2001cites this paper
• Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy

  2001cites this paper
• Oral nutritional supplementation is effective in the maintenance of remission in Crohn's disease.

  2000cites this paper
• Does the Initial Location of Crohn's Disease Have an Influence on the Time-to-relapse in Patients Under Maintenance Treatment with Oral Mesalamine?

  2000cites this paper
• Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.

  2000cites this paper
• Maintenance therapy in Crohn's disease.

  2000cites this paper
• Therapy of Crohn’s Disease in Childhood

  2000cites this paper
• Therapy for Crohn disease

  2000cites this paper
• Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI.

  2000cites this paper
• Gastrointestinal spread of oral prolonged‐release mesalazine microgranules (Pentasa) dosed as either tablets or sachet

  2000cites this paper
• Update in Medical Treatment of Crohn's Disease

  2000cites this paper
• Prevention of relapse of Crohn's disease.

  2000cites this paper
• Prolonged-Release Mesalazine

  2000cites this paper
• Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.

  1999cites this paper
• Current treatment for prevention of relapse and recurrence in Crohn's disease.

  1999cites this paper
• Mesalamine for prophylaxis of small bowel Crohn’s disease recurrence

  1999cites this paper